Conference Presentations, Posters & Abstracts
—
Past Pharsight®
Contributions
2010
November
Bruno R. Modeling of the Tumor Growth: Survival Link During Anti-Cancer Treatment. [invited presentation as part of symposium on "Progress in Modeling Disease Progression.”]. Presented at: American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition. November 14-18, 2010; New Orleans, LA.
Claret L, Lu JF, Bruno R, Sikorski R, Hei YJ, Sun YN. Use of a Public Domain Drug-Disease Modeling Framework and Phase II Data to Simulate Phase III Studies of Motesanib Plus Carboplatin/Paclitaxel or Bevacizumab Plus Carboplatin/Paclitaxel Versus Carboplatin/Paclitaxel Alone in First-Line Treatment of Non–Small Cell Lung Cancer. [poster presentation]. Presented at: Pharmacokinetics UK (PKUK); November 3-5, 2010; Bristol, England.
Rohatagi S, Carrothers TJ, Song S, Green M, Moore H, Lee J, Heyrman R, Wang A, Salazar DE. A FIXED-DOSE COMBINATION OF OLMESARTAN MEDOXOMIL (OM), AMLODIPINE (AML), AND HYDROCHLOROTHIAZIDE (HCTZ): USE OF MODELING AND SIMULATION TO SUPPORT APPROVAL OF INTERMEDIATE DOSE COMBINATIONS NOT INCLUDED IN THE PIVOTAL PHASE 3 STUDY. [poster presentation]. Presented at: American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition. November 14-18, 2010; New Orleans, LA.
September
Harnisch L, Chanu P, Dykstra K, Claret L, Bruno R, Gao X. Hemodynamics as a substitute for exercise capacity endpoints in patients with pulmonary arterial hypertension (PAH): A model based assessment for sildenafil. [oral presentation]. Presented at: European Respiratory Society (ERS); September 19, 2010; Barcelona, Spain.
Savant I, Mouksassi MS, Kassir N, Marier JF, Zhu W, Lau H. Population Pharmacokinetics of Apremilast (CC-1004) in Subjects with Active Psoriatic Arthritis. [poster presentation]. Presented at: American College of Clinical Pharmacology (ACCP) 39th Annual Meeting; September 12-14, 2010; Baltimore, MD.
Fenneteau F, Gosselin NH, Mouksassi MS, Marier JF, Tarral A, Merdjan H.
Population Pharmacokinetics Analysis of Linopristin and Flopristin in Plasma and Interstitial Fluid Following Repeated BID Oral Administration of NXL103. [poster presentation]. Presented at: 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); September 12-15, 2010; Boston, MA.
Martin DE, Pheng LH, Trinh M, Marier JF, Driz R, Ogden R, Palleja A. Lack of Differences in Pharmacokinetics of TBR-652, a Chemokine Receptor 5 (CCR5) Antagonist, in Healthy Subjects and HIV-1-Infected Subjects. [poster presentation]. Presented at: 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); September 12-15, 2010; Boston, MA.
Marier JF, Trinh MM, Chang C, Ge Y, Benziger D. Pharmacokinetics of a Novel
Anti-Pseudomonal Cephalosporin, CXA-101, and Tazobactam (CXA/TAZ) in Healthy Adult Subjects. [poster presentation]. Presented at: 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); September 12-15, 2010; Boston, MA.
August
Chanu P. Mechanistic Models to Simulate Dose Response of IgE Suppression Following Dosing of Anti-IgE Monoclonal Antibodies. [invited webinar]. AAPS eLearning Series; August 5, 2010.
June
Carrothers TJ. The Clinical Utility IndexSM, a Method for Balancing Efficacy and Safety in Drug Development Decision-Making. [invited presentation]. Presented at: Pacific Coast Statisticians and Pharmacometricians Innovation Conference (PaSiPhIC); June 14-16, 2010; San Luis Obispo, CA.
Chanu P, Agoram B, Bruno R. Mechanistic Models to Simulate Dose Response of IgE Suppression Following Dosing of Anti-IgE Monoclonal Antibodies. [oral presentation]. Presented at: 19th Annual Meeting of the Population Approach Group in Europe (PAGE); June 8-11, 2010; Berlin, Germany.
Ezzet F, Prins K, Boucher M. Modeling Adverse Event rates of Opioids for the Treatment of Osteoarthritis Pain using Literature Data. [poster presentation]. Presented at: 19th Annual Meeting of the Population Approach Group in Europe (PAGE); June 8-11, 2010; Berlin, Germany.
Ezzet F, Ribbing J. Bronchial Allergen Challenge in Asthma: A Model for Inhaled Corticosteroids (ICS) and Montelukast using Literature Summary Data. [poster presentation]. Presented at: 19th Annual Meeting of the Population Approach Group in Europe (PAGE); June 8-11, 2010; Berlin, Germany.
Ezzet F. Analysis of Adverse Events using Literature Data: a Simulation Study. [poster presentation]. Presented at: 19th Annual Meeting of the Population Approach Group in Europe (PAGE); June 8-11, 2010; Berlin, Germany.
Jonsson F, Claret L, Knight R,
Olesnyskyj
M, Jacques C, Rajkumar VS, Bruno R.
A Longitudinal Tumor Growth Inhibition Model Based on Serum M-Protein Levels in Patients With Multiple Myeloma Treated by Dexamethasone. [poster presentation]. Presented at: 19th Annual Meeting of the Population Approach Group in Europe (PAGE); June 8-11, 2010; Berlin, Germany.
Frances N, Claret L, Stark FS, Bruno R, Iliadis A. Influence analysis explores heterogeneity in database before data processing by a parametric population method. [poster presentation]. Presented at: 19th Annual Meeting of the Population Approach Group in Europe (PAGE); June 8-11, 2010; Berlin, Germany.
Marouani H, Claret L, Faivre C, Iliadis A. Nonparametric Approach using Gaussian Kernels Estimates Multivariate Probability Densities in Population Pharmacokinetics. [poster presentation]. Presented at: 19th Annual Meeting of the Population Approach Group in Europe (PAGE); June 8-11, 2010; Berlin, Germany.
Dunlavey MR. Derivation of SAEM C-matrix in Phoenix. [poster presentation]. Presented at: 19th Annual Meeting of the Population Approach Group in Europe (PAGE); June 8-11, 2010; Berlin, Germany.
Leary RH. Quasi-Monte Carlo EM Methods for NLME Analysis. [poster presentation]. Presented at: 19th Annual Meeting of the Population Approach Group in Europe (PAGE); June 8-11, 2010; Berlin, Germany.
May
Beliveau M. Integrating QSARs and PBPK Models. [invited presentation]. To be presented at: 14th International Workshop on Quantitative Structure-Activity Relationships in Envinronmental and Health Sciences, Post Conference Course.
May 28, 2010; Montreal, Quebec, Canada.
Marier JF. Biomarkers and Exposure-Response Modeling: Turning PK/PD Data into Knowledge in Non-Clinical and Clinical Studies. [invited presentation]. Presented at: Discovery to Development Symposium on Preclinical Oncology and Biomarkers. May 11, 2010; Montreal, Quebec.
Poland B, Bruno R, Claret L. Optimizing Oncology Drug Development with Modeling and Simulation. [invited presentation]. Presented at: American Course on Drug Development and Regulatory Sciences (ADCRS), Session 3: Learning and Confrming Trials: Finding and Confirming the Right Dose. May 3-6, 2010; Washington, DC.
Rohatagi S, Carrothers TJ, Song S, Green M, Moore H, Lee J, Heyrman R, Wang A, Salazar DE. A FIXED-DOSE COMBINATION OF OLMESARTAN MEDOXOMIL (OM), AMLODIPINE (AML), AND HYDROCHLOROTHIAZIDE (HCTZ): USE OF MODELING AND SIMULATION TO SUPPORT APPROVAL OF INTERMEDIATE DOSE COMBINATIONS NOT INCLUDED IN THE PIVOTAL PHASE 3 STUDY. [poster presentation]. Presented at: American Society of Hypertension 25th Annual Scientific Meeting and Exposition. May 1-4, 2010; New York, New York.
April
Claret L, Jonsson F, Jacques C. Rajkumar VS, Bruno R. A Drug Independent Tumor Burden Reduction-Survival Model in Patients with Multiple Myeloma to Support Early Clinical Development Decisions. [poster presentation]. Presented at: 6th International Symposium on Measurement and Kinetics of In Vivo Drug Effects; April 21-24, 2010; Noordwijkerhout, The Netherlands.
Chittenden J. Estimating a Time-Variant Pharmacokinetic Parameter as a Random Process. [poster presentation]. Presented at: 6th International Symposium on Measurement and Kinetics of In Vivo Drug Effects; April 21-24, 2010; Noordwijkerhout, The Netherlands.
March
Mouksassi S, Leonard P, Marier JF, Beliveau M . Allometric Scaling To Predict Clearance (CL) of a Recombinant Protein (ENB-0040) in Infants and Adults. [poster presentation]. Presented at: Society of Toxicology 2010 Annual Meeting; March 7-11, 2010; Salt Lake City, Utah.
Jomphe C, Lemire I, Leonard P, Reimer ML, Marier JF, Beliveau M. Comparison of the Toxicokinetic (TK) parameters of a Recombinant Protein (ENB-0040) estimated by Non-Compartmental and Compartmental Population Analysis following multiples doses in rats. [poster presentation]. Presented at: Society of Toxicology 2010 Annual Meeting; March 7-11, 2010; Salt Lake City, Utah.
Bruno R, Claret L. Modeling and Simulation of Clinical Tumor Progression Dynamics: Predicting Phase 3 Survival Outcomes from Tumor Size Measurements in Phase 2. [invited presentation]. Presented at: ASCPT 2010 Annual Meeting; March 17-20, 2010; Atlanta, Georgia.
Pan CP, Marier JF, Mouksassi MS, Breitmeyer JB, Royal MA. POPULATION PHARMACOKINETICS OF INTRAVENOUS ACETAMINOPHEN IN NEONATES, INFANTS, CHILDREN AND ADOLESCENTS. [oral presentation]. Presented at: ASCPT 2010 Annual Meeting; March 17-20, 2010; Atlanta, Georgia.
Gibbs J, Fredrickson J, Barbee T, Correa I, Smith B, Lin SL, Gibbs M . Quantitative Model of the Relationship between DPP-4 inhibition and Response: Meta-analysis of Alogliptin, Saxagliptin, Sitagliptin, and Vildagliptin Efficacy Results. [poster presentation]. Presented at: ASCPT 2010 Annual Meeting; March 17-20, 2010; Atlanta, Georgia.
Monteleone JP, Dykstra KH, Lee B, McGuire BM, Berry S, Diaz G, Rhead W, Syplyviy V, Zupanets I, Gargosky S, Martinez A, Mokhtarani M, Scharschmidt B. GLYCEROL PHENYLBUTRYATE (HPN-100), A NOVEL INVESTIGATIONAL AMMONIA SCAVENGING AGENT, DEMONSTRATED UNIQUE BEHAVIOR BASED ON PHARMACOKINETIC / PHARMACODYNAMIC (PK/PD) MODELING. [poster presentation]. Presented at: SOCIETY FOR INHERITED METABOLIC DISORDERS 2010 Annual Meeting; March 27-31, 2010; Albuquerque, New Mexico.
January
Bruno, R. Pharmacokinetics/pharmacodynamics of monoclonal antibody in Oncology. [invited presentation]. Presented at: 31st Annual EORTC-PAMM Group Meeting: Treatment Individualization of Cancer; January 27-30, 2009; Toulouse, France.